NC
EBS icon

NinePointTwo Capital’s Emergent Biosolutions EBS Stock Holding History

NinePointTwo Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,355
Closed -$259K – 198
2022
Q2 		$259K Hold
8,355
– – 0.09% 138
2022
Q1 		$343K Buy
+8,355
New +$369K 0.09% 97

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NinePointTwo Capital's EBS Position: Q3 2022 in Review

NinePointTwo Capital sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 8,355 shares — an estimated $259K sold.

NinePointTwo Capital first reported a position in EBS in Q1 2022 and held it in 2 quarters. The position peaked at $343K in Q1 2022. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

  • NinePointTwo Capital reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
  • NinePointTwo Capital sold 8,355 Emergent Biosolutions shares in Q3 2022, an estimated $259K.
  • NinePointTwo Capital first reported a position in Emergent Biosolutions in Q1 2022 and held it in 2 quarters.
  • NinePointTwo Capital's Emergent Biosolutions position peaked at $343K in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on NinePointTwo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.